EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer

Maria Vittoria Di Marco iD, Alessandro Gasparetto iD, Roberto Chiarle iD, Claudia Voena iD

Cells · 2025

DOI: 10.3390/cells14241991 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Maria Vittoria Di Marco und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, University of Turin, 10124 Turin, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Resistance, Neoplasm, Receptors, Cytoplasmic and Nuclear, Karyopherins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Italian Association for Cancer Research, Compagnia di San Paolo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, with therapeutic resistance continuing to limit long-term responses. Among emerging resistance mechanisms, dysregulation of nucleocytoplasmic transport has gained attention for its ability to inactivate tumor suppressor pathways. Exportin 1 (XPO1), the primary nuclear export protein, is frequently overexpressed in NSCLC and promotes the cytoplasmic mislocalization of proteins involved in cell cycle control, apoptosis, and DNA repair. This includes key regulators such as p53, FOXO, and RB, whose inactivation supports tumor progression and therapy resistance. Inhibition of XPO1 with selective inhibitors of nuclear export (SINE) compounds, including selinexor, has demonstrated the ability to restore nuclear localization and function of these proteins, thereby enhancing cellular sensitivity to DNA-damaging agents, kinase inhibitors, and immunotherapies. In preclinical NSCLC models, XPO1 inhibition has shown efficacy both as monotherapy and in combination strategies, with particular promise in KRAS- and EGFR-driven tumors. This review explores the role of XPO1 in NSCLC biology and therapy resistance, the rationale for targeting nuclear export, and the current landscape of XPO1-directed clinical development in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsDrug Resistance, NeoplasmReceptors, Cytoplasmic and NuclearKaryopherinsCarcinoma, Non-Small-Cell LungMolecular Targeted TherapyHumansExportin 1 ProteinAnimalsActive Transport, Cell NucleusHydrazinesTriazoles

Stichwörter der Autor:innen

NSCLCTP53XPO1drug resistance

Substanzen

Exportin 1 ProteinReceptors, Cytoplasmic and NuclearKaryopherinsselinexorHydrazinesTriazoles

Autor:innen und Institutionen

  • Department of Molecular Biotechnology and Health Sciences, University of Turin, 10124 Turin, Italy.
  • Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Department of Hemopathology, European Institute of Oncology (IEO), 20141 Milan, Italy.

ORCID-Profile: Maria Vittoria Di Marco, Alessandro Gasparetto, Roberto Chiarle, Claudia Voena

Förderung

  • NCI NIH HHS
  • Italian Association for Cancer Research
  • Compagnia di San Paolo
  • NIH HHS
  • Fondazione CRT and AIRC IG 2019
  • Dana Farber/Harvard Cancer Center SPORE in Lung Cancer

Zitieren

APA

Di Marco, M. V., Gasparetto, A., Chiarle, R., & Voena, C. (2025). Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer. Cells. https://doi.org/10.3390/cells14241991

Vancouver

Di Marco MV, Gasparetto A, Chiarle R, Voena C. Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer. Cells. 2025. doi:10.3390/cells14241991

BibTeX
@article{DiMarco2025,
  author = {Di Marco, Maria Vittoria and Gasparetto, Alessandro and Chiarle, Roberto and Voena, Claudia},
  title = {Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14241991}
}
Kostenlos starten →